The earnings call presented a balanced view with significant advancements in clinical development and a strong financial position, offset by increased expenses and challenges in trial execution timing. The overall sentiment is cautiously optimistic, given the potential positive outcomes from ongoing trials and strategic focus on innovation.

Company Guidance -

Q1 2026

During the Vistagen Therapeutics Fiscal Year-End 2025 Corporate Update Conference Call, the company provided detailed guidance on its progress and future plans. For the fiscal year ending March 31, 2025, research and development expenses increased to $39.4 million from $20 million in the previous year, driven by increased clinical and manufacturing activities. General and administrative expenses rose to $17.1 million from $14.1 million, primarily due to higher headcount and consulting fees. The net loss attributable to common shareholders was $51.4 million, compared to $29.4 million the previous year. Vistagen reported $80.5 million in cash and equivalents. The company's lead product, fasedienol, is in Phase III development, with top-line data from the PALISADE-3 trial expected in the fourth quarter of 2025 and results from PALISADE-4 anticipated in the first half of 2026. The company also highlighted progress in its other programs, including itruvone for major depressive disorder and PH80 for women's health, as well as participation in a CEO forum with FDA leadership aimed at fostering a collaborative regulatory environment.

Progress in Neuroscience Pipeline

Vistagen has made significant progress in its neuroscience pipeline with five clinical-stage pherine product candidates, each showing potential therapeutic benefits and favorable safety profiles.

Phase III Development for Fasedienol

Fasedienol is in Phase III development for the acute treatment of social anxiety disorder (SAD), a condition affecting over 31 million U.S. adults, with PALISADE-3 and PALISADE-4 trials ongoing and top-line results expected soon.

Advancements in Women's Health

PH80, a pherine product candidate for women's health indications, is advancing as a potential hormone-free treatment for menopausal hot flashes and has shown positive signals in other women's health conditions.

Strong Financial Position

As of March 31, 2025, Vistagen had $80.5 million in cash, cash equivalents, and moderate securities, providing a solid financial base for ongoing and future developments.

VistaGen Therapeutics (VTGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VTGN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2025	2026 (Q1)	-0.47 / -	-0.35	―	―	―
Jun 17, 2025	2025 (Q4)	-0.50 / -0.43	0.3	-243.33% (-0.73)	―
Feb 13, 2025	2025 (Q3)	-0.51 / -0.46	-0.22	-109.09% (-0.24)	―
Nov 07, 2024	2025 (Q2)	-0.39 / -0.42	-0.66	36.36% (+0.24)	―
Aug 13, 2024	2025 (Q1)	-0.40 / -0.35	-0.94	62.77% (+0.59)	―
Jun 11, 2024	2024 (Q4)	-0.36 / 0.30	-1.61	118.63% (+1.91)	―
Feb 13, 2024	2024 (Q3)	-0.30 / -0.22	-1.5	85.33% (+1.28)	―
Nov 09, 2023	2024 (Q2)	-0.68 / -0.66	-2.4	72.50% (+1.74)	―
Aug 10, 2023	2024 (Q1)	-0.86 / -0.94	-3	68.67% (+2.06)	―
Jun 28, 2023	2023 (Q4)	-1.50 / -1.61	-2.4	32.92% (+0.79)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VTGN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jun 17, 2025	$2.38	$2.06	-13.45%
Feb 13, 2025	$2.85	$2.97	+4.21%
Nov 07, 2024	$3.12	$3.14	+0.64%
Aug 13, 2024	$3.39	$3.28	-3.24%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does VistaGen Therapeutics (VTGN) report earnings?

VistaGen Therapeutics (VTGN) is schdueled to report earning on Aug 07, 2025, TBA (Confirmed).

What is VistaGen Therapeutics (VTGN) earnings time?

VistaGen Therapeutics (VTGN) earnings time is at Aug 07, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VTGN EPS forecast?

VTGN EPS forecast for the fiscal quarter 2026 (Q1) is -0.47.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing